Long term treatment of Huntington disease with L-glutamate and pyridoxine.
Neurology, 1978/12;28(12):1280-2.
Barr AN, Heinze W, Mendoza JE, Perlik S
PMID: 153484
Impact factor: 11.8
Abstract
Decreased levels of gamma aminobutyric acid (GABA) and its synthetic enzyme, glutamic acid decarboxylase, have been found in the brains of patients with Huntington disease. In an attempt to augment GABA-mediated neurotransmission, daily doses of 25 gm of L-glutamate (the substrate for glutamic acid decarboxylase) and 500 mg of pyridoxine, its cofactor, were given to five patients with Huntington disease. This regimen was continued for 2 years. Assessment of motor and behavioral function indicated no improvement on this regimen.
MeSH terms
Adult; Brain; Female; Glutamates; Humans; Huntington Disease; Long-Term Care; Male; Middle Aged; Pyridoxine; gamma-Aminobutyric Acid
More resources
EndNote: Download